Drugs / Ivonescimab
Ivonescimab
also known as
AK-112 · SMT112 · Envafolimab · Evoximab · Ivonescimab Injection · ivosidan · Ivosimab
Trials 159 · started per year
today
1
1
1
5
9
9
25
67
41
2010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT07650825 | Aug 2026 → Jan 2027 expected | cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07363408 | Jul 2026 → Jul 2027 expected | colorectal carcinoma | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07619339 | May 2026 → May 2029 expected | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07340476 | Dec 2025 → Apr 2026 overdue | — | Akeso | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06913218 | Jul 2025 → Feb 2028 expected | pancreatic ductal adenocarcinoma | Akeso | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06990620 | Jun 2025 → Jun 2027 expected | hepatocellular carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06868732 | Apr 2025 → Jun 2028 expected | non-small cell lung carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06424626 | May 2024 → Dec 2027 expected | metastatic melanoma, mucosal melanoma | Peking University Cancer Hospital & Institute | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT05116007 | Mar 2021 → Dec 2023 | small cell lung carcinoma | Akeso | Completed | No outcome recorded |
| Phase 1 | NCT04047290 | Sep 2019 → Feb 2024 | cancer | Akeso Biopharma, Inc. | Completed | No outcome recorded |
| Phase 1/231 trials | ||||||
| Phase 1/2 | NCT07602855 | Sep 2026 → Jul 2029 expected | cancer | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07590531 | Jun 2026 → May 2027 expected | non-small cell lung carcinoma | Multitude Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07623356 | Jun 2026 → Jun 2028 expected | non-small cell lung carcinoma | Akeso | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07560124 | Jun 2026 → Jun 2028 expected | breast cancer | Akeso | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07594522 | May 2026 → May 2028 expected | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07535463 | Apr 2026 → Apr 2028 expected | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07535437 | Apr 2026 → Apr 2028 expected | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07357220 | Mar 2026 → Feb 2027 expected | metastasis from malignant tumor of colon | Akeso | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07339839 | Mar 2026 → Sep 2027 expected | non-small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07397338 | Jan 2026 → May 2029 expected | colorectal cancer, metastatic neoplasm, non-small cell lung carcinoma | Revolution Medicines, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07385001 | Jan 2026 → Jan 2027 expected | esophageal squamous cell carcinoma | Tang-Du Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07208773 | Oct 2025 → Jan 2027 expected | non-small cell lung carcinoma, small cell lung carcinoma | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06957561 | Apr 2025 → May 2026 overdue | urinary bladder carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06938321 | Apr 2025 → May 2027 expected | biliary tract cancer | Akeso | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06809517 | Mar 2025 → Mar 2026 overdue | neoplastic meningitis | Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06844422 | Feb 2025 → Feb 2028 expected | malignant pancreatic neoplasm | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06672575 | Jan 2025 → Jan 2028 expected | glioblastoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06646055 | Jan 2025 → Dec 2026 expected | pancreatic ductal adenocarcinoma | Akeso | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06196814 | Oct 2024 → Mar 2026 overdue | — | Hunan Province Tumor Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06530251 | Sep 2024 → Jun 2026 overdue | hepatocellular carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06472895 | Jul 2024 → Dec 2025 overdue | renal cell carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05951608 | Oct 2023 → May 2026 overdue | cancer | Akeso | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05904379 | Jul 2023 → Jun 2026 overdue | non-small cell lung carcinoma | Akeso | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05846867 | May 2023 → May 2026 overdue | colorectal cancer | Akeso | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05689853 | Apr 2023 → Dec 2026 expected | cancer | Akeso | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05636267 | Feb 2023 → Feb 2025 | non-small cell lung carcinoma | Akeso | Terminated | No outcome recorded |
| Phase 1/2 | NCT05229497 | May 2022 → Dec 2026 expected | cancer | Akeso | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05214482 | Jan 2022 → Nov 2025 | cancer | Akeso | Completed | No outcome recorded |
| Phase 1/2 | NCT04999605 | Jun 2021 → Jun 2022 | ovarian carcinoma | Akeso | Terminated | No outcome recorded |
| Phase 1/2 | NCT04900363 | May 2021 → Jun 2024 | non-small cell lung carcinoma | Akeso | Completed | No outcome recorded |
| Phase 1/2 | NCT04597541 | Oct 2020 → Mar 2022 | cancer | Akeso | Completed | No outcome recorded |
| Phase 2100 trials | ||||||
| Phase 2 | NCT07655570 | Nov 2026 → May 2027 expected | skin angiosarcoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07359456 | Aug 2026 → Aug 2029 expected | colorectal cancer | UNICANCER | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07393555 | Aug 2026 → Nov 2028 expected | non-small cell lung carcinoma | SWOG Cancer Research Network | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07712094 | Aug 2026 → Feb 2029 expected | neuroendocrine neoplasm | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07064902 | Aug 2026 overdue | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07650838 | Aug 2026 → Dec 2027 expected | soft tissue sarcoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07669779 | Jul 2026 → Aug 2027 expected | non-small cell lung carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 2 | NCT07630077 | Jul 2026 → Jul 2027 expected | non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07158489 | Jul 2026 → Jul 2028 expected | non-small cell lung carcinoma | Swiss Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07603791 | Jun 2026 → Dec 2027 expected | non-small cell lung carcinoma | Shanghai Allink Biotherapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07636772 | Jun 2026 → Aug 2028 expected | urothelial carcinoma | Akeso | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07226544 | Jun 2026 → Sep 2027 expected | clear cell renal carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07244978 | Jun 2026 → Dec 2027 expected | esophageal squamous cell carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07591090 | Jun 2026 → Sep 2027 expected | female breast carcinoma | Akeso | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07412262 | May 2026 → Mar 2028 expected | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07405190 | May 2026 → Mar 2028 expected | disease of genetic or genomic mechanism, non-small cell lung carcinoma | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07565389 | May 2026 → May 2031 expected | nasopharyngeal carcinoma | National University Hospital, Singapore | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07489703 | Apr 2026 → Dec 2027 expected | non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07647016 | Apr 2026 → Dec 2027 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07516925 | Apr 2026 → Apr 2029 expected | leiomyosarcoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07057791 | Mar 2026 → Dec 2027 expected | small cell lung carcinoma | PrECOG, LLC. | Recruiting | No outcome recorded |
| Phase 2 | NCT07472478 | Mar 2026 → Dec 2027 expected | non-small cell lung carcinoma | Guangdong Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06951646 | Mar 2026 → Jul 2028 expected | non-small cell lung carcinoma | Second Xiangya Hospital of Central South University | Recruiting | No outcome recorded |
| Phase 2 | NCT07374250 | Feb 2026 → Dec 2027 expected | gastric cancer | Sichuan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07381075 | Feb 2026 → Oct 2028 expected | head and neck squamous cell carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07669051 | Jan 2026 → Jan 2028 expected | non-small cell lung carcinoma | Shandong Cancer Hospital and Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07394218 | Dec 2025 → Mar 2028 expected | Her2-receptor negative breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07244965 | Dec 2025 → Jul 2027 expected | cervical carcinoma | Women's Hospital School Of Medicine Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07241819 | Nov 2025 → Nov 2027 expected | non-small cell lung carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06846346 | Nov 2025 → Sep 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma | UNICANCER | Recruiting | No outcome recorded |
| Phase 2 | NCT07094685 | Nov 2025 → Aug 2027 expected | head and neck squamous cell carcinoma | University of Michigan Rogel Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07229417 | Oct 2025 → Sep 2027 expected | invasive lobular breast carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07070466 | Oct 2025 → Dec 2026 expected | esophageal cancer, gastric cancer | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06529718 | Oct 2025 → Aug 2027 expected | biliary tract cancer | UNICANCER | Recruiting | No outcome recorded |
| Phase 2 | NCT07204548 | Oct 2025 → Oct 2027 expected | non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07114315 | Sep 2025 → Aug 2027 expected | malignant pancreatic neoplasm | Akeso | Recruiting | No outcome recorded |
| Phase 2 | NCT06848842 | Sep 2025 → Jun 2027 expected | metastasis from malignant tumor of colon | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT07103447 | Sep 2025 → Dec 2027 expected | female breast carcinoma | Shuangyue Liu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07158840 | Sep 2025 → Sep 2028 expected | non-small cell lung carcinoma | Akeso | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07162714 | Sep 2025 → Jun 2026 overdue | rectal cancer | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07130240 | Aug 2025 → Aug 2028 expected | cervical cancer | Obstetrics & Gynecology Hospital of Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06904300 | Aug 2025 → Apr 2028 expected | gastric cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07021950 | Aug 2025 → Oct 2027 expected | colorectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07095803 | Aug 2025 → Feb 2026 overdue | multiple polyglandular tumor | Sheng Zhang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07086326 | Jul 2025 → Dec 2026 expected | non-small cell lung carcinoma | Yang Fan, MD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06959550 | Jul 2025 → Jul 2028 expected | colorectal cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07038915 | Jul 2025 | squamous cell lung carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT07017673 | Jul 2025 → Dec 2027 expected | triple-negative breast carcinoma | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07091227 | Jul 2025 → Jul 2026 overdue | gastroesophageal adenocarcinoma | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07052253 | Jul 2025 → May 2027 expected | hepatocellular carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 2 | NCT06980077 | Jul 2025 → Jun 2027 expected | thymic carcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06940518 | Jul 2025 → Jan 2028 expected | clear cell renal carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07188103 | Jul 2025 → Jun 2027 expected | esophageal squamous cell carcinoma | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06840834 | Jun 2025 → Mar 2026 overdue | pleural mesothelioma | French Cooperative Thoracic Intergroup | Recruiting | No outcome recorded |
| Phase 2 | NCT07070479 | Jun 2025 → Jan 2027 expected | nasopharyngeal carcinoma | Ming-Yuan Chen | Recruiting | No outcome recorded |
| Phase 2 | NCT06991491 | Jun 2025 → Jun 2026 overdue | malignant pancreatic neoplasm | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07009925 | Jun 2025 → May 2027 expected | squamous cell lung carcinoma | Jiangsu Cancer Institute & Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06977542 | Jun 2025 → Jan 2029 expected | triple-negative breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06993025 | May 2025 → Apr 2026 overdue | biliary tract cancer | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06936644 | Apr 2025 → Apr 2027 expected | respiratory system cancer | Shanghai Chest Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06790212 | Apr 2025 → Aug 2027 expected | colon carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06925724 | Apr 2025 → Apr 2027 expected | cervical cancer, endometrial cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06944106 | Mar 2025 → Apr 2026 overdue | malignant pancreatic neoplasm | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06875076 | Mar 2025 → Jan 2028 expected | malignant pleural mesothelioma | The First Hospital of Jilin University | Recruiting | No outcome recorded |
| Phase 2 | NCT06814158 | Mar 2025 → Jul 2026 overdue | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06820762 | Feb 2025 → Dec 2026 expected | small cell lung carcinoma | The Second Affiliated Hospital of Dalian Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06805617 | Feb 2025 → Jul 2026 overdue | salivary gland adenoid cystic carcinoma | Glenn J. Hanna | Recruiting | No outcome recorded |
| Phase 2 | NCT06686030 | Feb 2025 → Oct 2027 expected | carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 2 | NCT06814067 | Feb 2025 → Feb 2029 expected | head and neck squamous cell carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06718543 | Feb 2025 → Oct 2026 expected | rectal cancer | fan li | Recruiting | No outcome recorded |
| Phase 2 | NCT06769971 | Feb 2025 → Dec 2026 expected | small cell lung carcinoma | Sichuan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06769295 | Feb 2025 → Dec 2026 expected | non-small cell lung carcinoma | Sichuan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06760520 | Jan 2025 → Dec 2027 expected | — | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06750952 | Dec 2024 → Dec 2026 expected | thymus cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06793332 | Dec 2024 → Jan 2026 overdue | metastatic malignant neoplasm in the brain, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06567314 | Dec 2024 → Sep 2028 expected | skin squamous cell carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06402435 | Nov 2024 → Aug 2026 overdue | breast cancer | Hubei Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06489197 | Nov 2024 → Oct 2026 expected | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06560112 | Nov 2024 → May 2026 overdue | ovarian cancer | Akeso | Recruiting | No outcome recorded |
| Phase 2 | NCT06684873 | Nov 2024 → Dec 2027 expected | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06802666 | Oct 2024 → Sep 2026 expected | — | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT06478043 | Oct 2024 | small cell lung carcinoma | Zhejiang Cancer Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06620796 | Sep 2024 → Sep 2026 expected | small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06537011 | Aug 2024 → Jul 2027 expected | — | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06637007 | Aug → Dec 2024 overdue | bone sarcoma, soft tissue sarcoma | Shanxi Province Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06491472 | Jul 2024 → Jul 2026 overdue | malignant pancreatic neoplasm | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT06791148 | Jul 2024 → Jul 2027 expected | gastric cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT06444009 | Jul 2024 → Dec 2025 overdue | head and neck squamous cell carcinoma | Lei Liu | Recruiting | No outcome recorded |
| Phase 2 | NCT06391008 | Apr → Dec 2024 | — | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 2 | NCT06375486 | Mar 2024 → Mar 2025 | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06196775 | Jan 2024 → Jan 2026 overdue | hepatocellular carcinoma | Harbin Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06145308 | Aug 2023 → Jul 2028 expected | salivary gland carcinoma | Peking Union Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05432492 | Aug 2022 → Apr 2025 | hepatocellular carcinoma | Akeso | Completed | No outcome recorded |
| Phase 2 | NCT05382442 | Jun 2022 → May 2026 overdue | colorectal cancer | Akeso | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05227664 | Mar 2022 → Dec 2026 expected | triple-negative breast carcinoma | Akeso | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05247684 | Feb 2022 → Aug 2025 overdue | non-small cell lung carcinoma | Akeso | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04870177 | Apr 2021 → May 2024 | endometrium neoplasm, female reproductive organ cancer, metastatic malignant neoplasm, ovarian neoplasm +1 | Akeso | Completed | No outcome recorded |
| Phase 2 | NCT04736823 | Feb 2021 → Jul 2026 overdue | non-small cell lung carcinoma | Akeso | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01042379 | Mar 2010 → Dec 2030 expected | HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT07264075 | May 2026 → May 2030 expected | head and neck squamous cell carcinoma | Groupe Oncologie Radiotherapie Tete et Cou | Recruiting | No outcome recorded |
| Phase 3 | NCT07228832 | Nov 2025 → May 2028 expected | colorectal cancer | Summit Therapeutics | Recruiting | No outcome recorded |
| Phase 3 | NCT06928389 | Jul 2025 → May 2027 expected | non-small cell lung carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 3 | NCT07010263 | Jun 2025 → Dec 2028 expected | small cell lung carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 3 | NCT06953999 | Jun 2025 → May 2027 expected | malignant pancreatic neoplasm | Akeso | Recruiting | No outcome recorded |
| Phase 3 | NCT06951503 | May 2025 → Jan 2027 expected | colorectal adenocarcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 3 | NCT06767514 | Feb 2025 → Apr 2028 expected | non-small cell lung carcinoma | Summit Therapeutics | Recruiting | No outcome recorded |
| Phase 3 | NCT06767527 | Feb 2025 → Dec 2026 expected | triple-negative breast carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 3 | NCT06601335 | Oct 2024 → Jan 2027 expected | head and neck squamous cell carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 3 | NCT06591520 | Oct 2024 → Oct 2026 expected | biliary tract cancer | Akeso | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05899608 | Oct 2023 → Dec 2028 expected | non-small cell lung carcinoma | Summit Therapeutics | Recruiting | No outcome recorded |
| Phase 3 | NCT05840016 | Aug 2023 → Feb 2025 overdue | non-small cell squamous lung carcinoma | Akeso | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06396065 | May 2023 → Apr 2025 overdue | non-small cell lung carcinoma | Summit Therapeutics | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05499390 | Nov 2022 → Jan 2024 overdue | non-small cell lung carcinoma | Akeso | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05184712 | Jan 2022 → Mar 2023 overdue | non-small cell lung carcinoma | Akeso | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06930573 | Dec 2024 → May 2026 overdue | hepatocellular carcinoma | The First Affiliated Hospital of Zhengzhou University | Recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06936488 | Mar 2025 → Oct 2026 expected | colorectal adenocarcinoma | Huai'an First People's Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT06766591 | Jan → Oct 2025 overdue | neoplastic meningitis, non-small cell lung carcinoma | Jiangsu Province Nanjing Brain Hospital | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07614646 Background | Jul 2026 → Jul 2028 expected | non-small cell squamous lung carcinoma | Everest Medicines (Beijing) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06877650 Background | Apr 2025 → Mar 2028 expected | cancer | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07234877 Background | Nov 2026 → Jan 2032 expected | non-small cell lung carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07245446 Background | Oct 2025 → Dec 2027 expected | small cell lung carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 2 | NCT06196697 Background | Apr 2024 → Jan 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Harbin Medical University | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07076693 Background | Jun 2025 → May 2028 expected | non-small cell lung carcinoma | Shanghai Chest Hospital | Active not recruiting | No outcome recorded |
Press releases naming this drug 10 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-07 | Akeso | 依沃西说明书重磅更新：AK112-301研究 OS 与 PFS 双阳性结果纳入 akesobio.com ↗ |
| 2023-08-06 | Akeso | 张力教授团队PD-1/VEGF双抗（AK112）治疗肺癌最新临床研究结果在《柳叶刀》子刊发布 akesobio.com ↗ |
| 2022-09-02 | Akeso | 康方生物依沃西(PD-1/VEGF双抗，AK112)一线治疗PD-L1表达阳性的NSCLC拟被CDE纳入突破性治疗品种 akesobio.com ↗ |
| 2022-03-24 | Akeso | PD-1/VEGF双抗(AK112)单药或联合化疗新辅助/辅助治疗可切除非小细胞肺癌的II期临床研究完成首例患者入组 akesobio.com ↗ |
| 2022-01-31 | Akeso | AK112（PD-1/VEGF双抗）治疗EGFR-TKI耐药的晚期非鳞非小细胞肺癌的III期临床完成首例患者给药 akesobio.com ↗ |
| 2022-01-10 | Akeso | CD47单抗（AK117）联合PD-1/VEGF双抗（AK112）联合或不联合化疗治疗恶性肿瘤的Ib/II临床研究获批开展 akesobio.com ↗ |
| 2021-11-15 | Akeso | 康方生物PD-1/VEGF双抗（AK112）治疗耐铂上皮卵巢癌的I期临床研究成果SITC 2021上发布 akesobio.com ↗ |
| 2021-11-02 | Akeso | PD-1/VEGF双抗(AK112)单药或联合化疗新辅助/辅助治疗可切除非小细胞肺癌的II期临床研究获批开展 akesobio.com ↗ |
| 2021-09-26 | Akeso | PD-1/VEGF双抗（AK112）联合化疗一线治疗晚期NSCLC的II期临床研究成果在2021 CSCO发布 akesobio.com ↗ |
| 2021-09-23 | Akeso | 2021CSCO|康方生物PD-1/VEGF双抗（AK112）两项肺癌和卵巢癌的II期临床研究成果发布 akesobio.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 168 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ivonescimab | “As the world's first PD-1/VEGF bispecific antibody, ivonescimab ((AK112) has shown superior systemic efficacy compared to conventional VEGF targeted therapy combined with...” NCT06809517 ↗110“This is an open-label, single arm , Ib/II phase trial to evaluate the efficacy and safety of AK112（ivonescimab）monotherapy as first-line treatment for favourable risk...” NCT06472895 ↗ “A Prospective, Parallel, Double-cohort, Multicenter Phase II Clinical Study of Ivonescimab (AK112) Combined With IP Chemotherapy ± TACE for First-line Treatment of Metastatic...” NCT07712094 ↗ “A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or...” PMID 37879536 ↗ Oct 2023 “A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined with Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for Resectable, Locally Advanced...” NCT07385001 ↗ “The advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation will receive the combination of fulzerasib (IBI351) with ivonescimab (AK-112) in...” NCT06936644 ↗ “Patients with squamous cell carcinoma received docetaxel administered in 3-week cycles, and patients with adenocarcinoma received pemetrexed, patinum and one of sintilimab or...” NCT07076693 ↗ “Ivonescimab (AK112) is a first-in-class bispecific antibody that simultaneously targets programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF) with cooperative binding.” PMID 40114411 ↗ Mar 2025 “The immunotherapy drug used is Ivonescimab (AK112) (20mg/kg) , administered every 3 weeks concurrently with chemotherapy for 8 cycles.” NCT06402435 ↗ “Ivonescimab is a humanized IgG1 bispecific anti-programmed cell death protein 1/vascular endothelial growth factor antibody.” PMID 39490738 ↗ Oct 2024 “Ivonescimab is a novel humanized tetrameric IgG-scFv bispecific antibody targeting PD-1 and VEGF.” NCT07130240 ↗ “Ivonescimab (20 mg/kg, IV, every 3 weeks) plus platinum-based chemotherapy” NCT06620796 ↗ “Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W)” NCT06944106 ↗ “Ivonescimab (SMT112 /AK112) Plus Pemetrexed and Carboplatin” NCT06396065 ↗ “ivonescimab (AK112/SMT112)” PMID 38642937 ↗ Apr 2024 |
| Known as | AK-112 | “A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR...” NCT06936488 ↗75“The advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation will receive the combination of fulzerasib (IBI351) with ivonescimab (AK-112) in...” NCT06936644 ↗ “All enrolled subjects will receive Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W) in combination with HAIC (utilizing the FOLFOX chemotherapy regimen)” NCT06375486 ↗ “Ivonescimab (AK112) is a novel PD-1/VEGF bispecific antibody designed to simultaneously block PD-1-mediated immune evasion and inhibit VEGF-driven angiogenesis.” NCT07064902 ↗ “Ivonescimab (AK112/SMT112) is a bispecific antibody targeting PD-1 and VEGF, designed to simultaneously modulate immune and angiogenic pathways.” NCT07158489 ↗ “This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.” NCT07208773 ↗ “Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles.” NCT05184712 ↗ “Ivonescimab(AK112) combined with chemotherapy in the treatment of advanced esophageal squamous cell carcinoma (ESCC).” NCT06489197 ↗ “Trastuzumab Rezetecan (SHR-A1811) combined with ivonescimab (AK112)” NCT07630077 ↗ “Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W)” NCT06944106 ↗ “Ivonescimab (AK112) + platinum-based doublet chemotherapy” NCT07086326 ↗ “ivonescimab (AK112) combined with chemotherapy” NCT06875076 ↗ “Ivonescimab (SMT112 or AK112) Injection” NCT06760520 ↗ “Ivonescimab (SMT112 or AK112) Injection” NCT06913218 ↗ “Ivonescimab（AK112) 20mg/kg, IV, Day 1” NCT07244978 ↗ “ivonescimab (AK112/SMT112)” PMID 38642937 ↗ Apr 2024 |
| Known as | Envafolimab | “combined with AK112 (Envafolimab) with or without chemotherapy” NCT06718543 ↗ |
| Known as | Evoximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06391008 ↗ |
| Known as | Ivonescimab Injection | “Drug: Ivonescimab Injection” NCT07228832 ↗ |
| Known as | ivosidan | “The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with ivosidan (AK112) in patients with advanced non-small cell lung cancer (NSCLC).” NCT07590531 ↗ |
| Known as | Ivosimab | “An Open-label, Multicenter Phase Ib/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMT116 in Combination With Ivosimab (AK112) in Patients With...” NCT07590531 ↗ |
| Known as | SMT112 | “Ivonescimab (AK112/SMT112) is a bispecific antibody targeting PD-1 and VEGF, designed to simultaneously modulate immune and angiogenic pathways.” NCT07158489 ↗5“Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles.” NCT05184712 ↗ “Ivonescimab (SMT112 /AK112) Plus Pemetrexed and Carboplatin” NCT06396065 ↗ “Ivonescimab (SMT112 or AK112) Injection” NCT06760520 ↗ “Ivonescimab (SMT112 or AK112) Injection” NCT06913218 ↗ “ivonescimab (AK112/SMT112)” PMID 38642937 ↗ Apr 2024 |
| Action | Inhibit | “Serum VEGF level was rapidly down-regulated after each administration.” PMID 40114411 ↗ Mar 2025 |
| Modality | Monoclonal antibody | “humanized IgG1 bispecific antibody” PMID 37593227 ↗ Aug 2023 |
| Route | Intravenous | “20 mg/kg IV Q3W monotherapy” NCT01042379 ↗ |